0000899243-22-028856.txt : 20220816
0000899243-22-028856.hdr.sgml : 20220816
20220816185441
ACCESSION NUMBER: 0000899243-22-028856
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220812
FILED AS OF DATE: 20220816
DATE AS OF CHANGE: 20220816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stuckley Carol
CENTRAL INDEX KEY: 0001863298
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35945
FILM NUMBER: 221171636
MAIL ADDRESS:
STREET 1: C/O CENTESSA PHARMACEUTICALS PLC
STREET 2: D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3FH
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Epizyme, Inc.
CENTRAL INDEX KEY: 0001571498
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261349956
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-229-5872
MAIL ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-12
1
0001571498
Epizyme, Inc.
EPZM
0001863298
Stuckley Carol
C/O EPIZYME, INC.,
400 TECHNOLOGY SQUARE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock, par value $0.0001
2022-08-12
4
D
0
25696
D
0
D
Reflects disposition of restricted stock units ("RSUs") in accordance with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any, and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022.
(Continued from Footnote 1) Pursuant to the Merger Agreement, effective immediately prior to the effective time of the Merger, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each share underlying such RSU, in each case, less applicable withholding.
/s/ John Weidenbruch, attorney-in-fact
2022-08-16